Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by AQR Capital Management LLC

Key Points

• AQR Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 13.9% owning approximately 0.22% of the company after purchasing additional shares.
• Regeneron Pharmaceuticals reported $12.89 earnings per share in its latest quarter, significantly surpassing the consensus estimate of $8.43.
• The company announced a quarterly dividend of $0.88 per share, with a current dividend yield of 0.6%.

AQR Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 235,950 shares of the biopharmaceutical company's stock after purchasing an additional 28,865 shares during the quarter. AQR Capital Management LLC owned approximately 0.22% of Regeneron Pharmaceuticals worth $148,665,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares in the last quarter. Nuveen LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $343,764,000. Pacer Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after buying an additional 303,785 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Regeneron Pharmaceuticals by 30.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after buying an additional 226,952 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday. Finally, BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $563.80 on Thursday. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,182.31. The stock has a market cap of $59.76 billion, a price-to-earnings ratio of 14.21, a P/E/G ratio of 1.93 and a beta of 0.35. The company's fifty day moving average is $560.61 and its 200 day moving average is $586.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the previous year, the firm posted $11.56 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.